Bank of America Corp DE Purchases 345,143 Shares of AngioDynamics, Inc. $ANGO

Key Points

• Bank of America acquired 345,143 AngioDynamics shares worth approximately $4.49 million, giving it about a 0.84% stake. Institutional investors collectively own 89.43% of the company.
• AngioDynamics exceeded quarterly earnings and revenue expectations, reporting an adjusted loss of $0.07 per share on $86.61 million in revenue, though it remains unprofitable and guides to a fiscal 2027 loss.
• Analyst sentiment is mixed: the stock carries a consensus “Hold” rating with a $19.50 target price, while insiders own 6% of shares and a senior vice president recently sold 23,370 shares.

Bank of America Corp DE bought a new stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 345,143 shares of the medical instruments supplier's stock, valued at approximately $4,490,000. Bank of America Corp DE owned about 0.84% of AngioDynamics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. bought a new position in AngioDynamics during the 2nd quarter worth approximately $49,480,000. Weber Capital Management LLC ADV bought a new position in AngioDynamics during the 2nd quarter worth about $17,649,392. Paradigm Capital Management Inc. NY bought a new position in AngioDynamics during the 2nd quarter worth about $8,732,000. Western Standard LLC acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $5,037,000. Finally, Manatuck Hill Partners LLC acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $3,597,000. 89.43% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares of the company's stock, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 6.00% of the company's stock.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $15.54 on Tuesday. The firm's 50-day moving average is $15.31 and its 200-day moving average is $12.89. The stock has a market cap of $642.27 million, a price-to-earnings ratio of -17.86 and a beta of 0.33. AngioDynamics, Inc. has a 52-week low of $9.39 and a 52-week high of $16.29.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analysts' expectations of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. Sell-side analysts predict that AngioDynamics, Inc. will post -0.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Wall Street Zen raised AngioDynamics from a "hold" rating to a "buy" rating in a research report on Saturday, August 22nd. Canaccord Genuity Group lifted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. HC Wainwright boosted their target price on AngioDynamics from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. Finally, Zacks Research cut shares of AngioDynamics from a "hold" rating to a "strong sell" rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $19.50.

About AngioDynamics

AngioDynamics, Inc NASDAQ: ANGO is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company's product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.